[go: up one dir, main page]

ES2175098T3 - Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. - Google Patents

Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.

Info

Publication number
ES2175098T3
ES2175098T3 ES96919173T ES96919173T ES2175098T3 ES 2175098 T3 ES2175098 T3 ES 2175098T3 ES 96919173 T ES96919173 T ES 96919173T ES 96919173 T ES96919173 T ES 96919173T ES 2175098 T3 ES2175098 T3 ES 2175098T3
Authority
ES
Spain
Prior art keywords
angiotensin
receptor antagonist
combination therapy
spironolactone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919173T
Other languages
English (en)
Inventor
Todd E Maclaughlan
Joseph R Schuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2175098T3 publication Critical patent/ES2175098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA TERAPIA DE COMBINACION QUE COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN ANTGONISTA DEL RECEPTOR DE ALDOSTERONA DEL TIPO ESPIROLACTONA LIBRE DE EPOXI Y UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II PARA EL TRATAMIENTO DE TRASTORNOS CIRCULATORIOS, INCLUYENDO TRASTORNOS CARDIOVASCULARES TALES COMO HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, CIRROSIS Y ASCITES. LOS ANTAGONISTAS PREFERIDOS DEL RECEPTOR DE ANGIOTENSINA II SON AQUELLOS COMPUESTOS QUE POSEEN UNA ELEVADA POTENCIA Y BIODISPONIBILIDAD Y QUE SE CARACTERIZAN POR POSEER UN GRUPO IMIDAZOL O TRIAZOL UNIDO A UNA PORCION DE BIFENILMETILO O PIRIDINIL / FENILMETILO. UN ANTAGONISTA DEL RECEPTOR DE ALDOSTERONA DEL TIPO ESPIROLACTONA LIBRE DE EPOXI ES ESPIRONOLACTONA. UNA TERAPIA DE COMBINACION PREFERIDA INCLUYE EL ANTAGONISTA DE RECEPTOR DE ANGIOTENSINA II 5 IL)METIL] DEL RECEPTOR DE ALDOSTERONA EPOXIMEXRENONA.
ES96919173T 1995-06-07 1996-06-05 Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. Expired - Lifetime ES2175098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48608995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2175098T3 true ES2175098T3 (es) 2002-11-16

Family

ID=23930539

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919173T Expired - Lifetime ES2175098T3 (es) 1995-06-07 1996-06-05 Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.

Country Status (16)

Country Link
US (1) US20040102423A1 (es)
EP (1) EP0831911B1 (es)
JP (1) JPH11509838A (es)
KR (1) KR19990022723A (es)
CN (1) CN1192696A (es)
AT (1) ATE216261T1 (es)
AU (1) AU6158096A (es)
BR (1) BR9608505A (es)
CA (1) CA2224222A1 (es)
CZ (1) CZ291268B6 (es)
DE (1) DE69620756T2 (es)
DK (1) DK0831911T3 (es)
ES (1) ES2175098T3 (es)
IL (1) IL122246A (es)
PT (1) PT831911E (es)
WO (1) WO1996040258A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
CA2382549C (en) 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
AU2005295167B2 (en) * 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
KR20120051760A (ko) 2006-04-04 2012-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
JP5869222B2 (ja) * 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP4892649B1 (ja) 2009-01-30 2012-03-07 武田薬品工業株式会社 縮合環化合物及びその用途
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103476410B (zh) * 2011-01-11 2020-02-21 戴麦里克斯生物科学有限公司 联合疗法
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
CN109715615A (zh) 2016-06-29 2019-05-03 蒙特利尔大学 联芳甲基杂环
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1991011999A1 (en) * 1990-02-13 1991-08-22 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
ATE216261T1 (de) 2002-05-15
CN1192696A (zh) 1998-09-09
DK0831911T3 (da) 2002-07-22
CA2224222A1 (en) 1996-12-19
US20040102423A1 (en) 2004-05-27
IL122246A (en) 2004-06-01
AU6158096A (en) 1996-12-30
EP0831911B1 (en) 2002-04-17
IL122246A0 (en) 1998-04-05
KR19990022723A (ko) 1999-03-25
CZ384897A3 (cs) 1998-05-13
BR9608505A (pt) 1999-07-06
CZ291268B6 (cs) 2003-01-15
EP0831911A2 (en) 1998-04-01
JPH11509838A (ja) 1999-08-31
PT831911E (pt) 2002-09-30
WO1996040258A3 (en) 1997-01-23
WO1996040258A2 (en) 1996-12-19
DE69620756T2 (de) 2002-11-14
DE69620756D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
ES2175098T3 (es) Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.
WO1996040255A3 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
NZ310730A (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
WO2004082599A3 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
DE69007740D1 (de) Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
IE902139L (en) Imidazolyl alkenoic acids
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
MY110205A (en) Imidazolyl-alkenoic acids.
IE902140L (en) Imidazolyl alkenoic acids
NZ330889A (en) Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
NO872863D0 (no) Analogifremgangsmaate for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-ii-reseptorer.
CA2110806A1 (en) 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity
AU641952B2 (en) Substituted N-(imidazolyl)alkyl alanine derivatives
MXPA05010507A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antiobesidad.
AU3635793A (en) Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
MX9709978A (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 831911

Country of ref document: ES